Volatilita spoločnosti Adma Biologics Inc
Aká je hodnota metriky Volatilita spoločnosti Adma Biologics Inc?
Hodnota metriky Volatilita spoločnosti Adma Biologics Inc je 4.49%
Aká je definícia metriky Volatilita?
Volatilita alebo percentuálny average true range (ATRP 14) je ATR vyjadrený ako percentuálny podiel z uzatváracej ceny.
Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks won't necessarily have lower ATR values than higher-priced stocks.
The period used in the calculation is 14 days and the normalized indicator oscillates between 0 and 100 percent of recent price variation. Importantly, the indicator doesn't predict the direction of price but it describes the current volatility. The volatility is comparable across all securities and all markets.
Volatility expresses the degree of price movement. The use of ATRP as volatility compared to ATR is preferred in cases when different securities or different time periods are compared. Examples are stock screening, filtering strategies, and studying seasonality and volatility patterns over long periods of time and different markets
Volatilita spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Adma Biologics Inc
Čomu sa venuje spoločnosť Adma Biologics Inc?
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Firmy s metrikou volatilita podobnou spoločnosti Adma Biologics Inc
- Hodnota metriky Volatilita spoločnosti Ventus VCT C je 4.48%
- Hodnota metriky Volatilita spoločnosti NeuroScientific Biopharmaceuticals je 4.48%
- Hodnota metriky Volatilita spoločnosti Zee Media je 4.48%
- Hodnota metriky Volatilita spoločnosti StarPower Semiconductor je 4.48%
- Hodnota metriky Volatilita spoločnosti Lords Chloro Alkali je 4.48%
- Hodnota metriky Volatilita spoločnosti Trigyn Technologies je 4.48%
- Hodnota metriky Volatilita spoločnosti Adma Biologics Inc je 4.49%
- Hodnota metriky Volatilita spoločnosti PDF Solutions je 4.50%
- Hodnota metriky Volatilita spoločnosti Enhabit je 4.50%
- Hodnota metriky Volatilita spoločnosti Avita Medical je 4.50%
- Hodnota metriky Volatilita spoločnosti Yanzhou Coal Mining Co je 4.50%
- Hodnota metriky Volatilita spoločnosti Goa Carbon je 4.50%
- Hodnota metriky Volatilita spoločnosti Rayonier Advanced Materials Inc je 4.50%